Clemson University baseball head coach Erik Bakich shares the mentality behind his team's decision to shake hands with ...

BioCity Biopharma’s selective endothelin receptor type A (ETA) antagonist has reduced excess proteins in the urine of ...

Assessment of proteinuria in addition to estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease (CKD) may help identify individuals at high risk of adverse outcomes ...

Sexual intercourse can cause proteinuria in men for up to 12 h, according to a small prospective study at the Israel Naval Medical Institute. When dipstick urine tests are positive for protein ...

The following is a summary of “Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy,” published in the ...

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) rose 7% following the company's announcement of its intent to submit a supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in the ...

Travere Therapeutics shares rose sharply in early trading Tuesday after the biopharmaceutical company said it plans to seek expanded Food and Drug Administration approval of its kidney-disease drug ...

Efficacy and safety of endoscopic retrograde cholangiopancreatography (ERCP) vs percutaneous transhepatic biliary drainage (PTBD) for cholangiocarcinoma biliary obstruction: An updated systematic ...

Biocity Biopharmaceutics Co. Ltd.’s selective endothelin receptor type A antagonist, SC-0062, met the primary endpoint of reducing proteinuria in a phase II diabetic kidney disease cohort. Conducted ...

About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Ingelheim, Germany Saturday, February 15, 2025, 12:00 Hrs [IST] ...